Share this article on:

Characterization of thrombin derived from human recombinant prothrombin

Lövgren, Anna; Deinum, Johannaa; Rosén, Steffenb; Bryngelhed, Piab; Rosén, Perb; Hansson, Kenny M.a

Blood Coagulation & Fibrinolysis: July 2015 - Volume 26 - Issue 5 - p 545–555
doi: 10.1097/MBC.0000000000000289
Original Articles

Thrombin (FIIa) is the key enzyme in haemostasis and acts on several substrates involved in clot formation, platelet activation and feed-back regulation of its own formation. During activation of blood coagulation, FIIa is formed by proteolytic cleavage of prothrombin (FII). In the production of recombinant human FII (rhFII), a key question is whether the thrombin formed has the same properties as endogenous thrombin. We have investigated whether FIIa formed from rhFII and plasma-derived human FII (pdhFII) have the same enzymatic and haemostatic properties against a number of substrates and the same haemostatic capacity in plasma, whole blood and on platelets. Pure FIIa was isolated from rhFII and pdhFII cleaved by recombinant ecarin, and analytical methods were developed to compare the activity of FIIa against different substrates. FIIa derived from rhFII and pdhFII were found to have very similar properties in activating FVIII, FXIII, protein C, platelet aggregation and plasma or whole blood coagulation. Further, the same turnover for S-2366 was found with similar K M. However, activation of FV with rhFIIa was approximately 25% more effective than with pdhFIIa and heparin-enhanced inhibition of rhFIIa by antithrombin was significantly more efficient compared with pdhFIIa with 10% higher inhibition both at steady state and at initial rate conditions. Although differences between the two FIIa preparations using ecarin cleavage were observed, FIIa derived from rhFII administered to human would likely be very similar in activity and function as FIIa formed from endogenous FII.

aCVMD iMED, AstraZeneca R&D, Mölndal

bRossix AB, Taljegårdsgatan 3B, Mölndal, Sweden

Correspondence to Kenny M. Hansson, CVMD iMED, AstraZeneca R&D, 43183 Mölndal, Sweden. Tel: +46 31 7065371; fax: +46 31 7763859; e-mail:

Received 5 December, 2014

Revised 23 January, 2015

Accepted 3 February, 2015

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Copyright © 2015 YEAR Wolters Kluwer Health, Inc. All rights reserved.